drugset / Trial / NCT01163838
Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of repeated doses of RN316 in eligible healthy volunteers. RN316 is an investigational drug that is currently being studied as a cholesterol lowering therapy.
Timeline
- Start
- 2010-08
- Primary completion
- 2011-03
- Completion
- 2011-03
Outcome
Outcome not reported
Stopped: “Study was redesigned based on FDA feedback.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bococizumab | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | Bococizumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Bococizumab | Monoclonal antibody | 4 mg/kg | Intravenous |
| Subject | Bococizumab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Bococizumab | Monoclonal antibody | 12 mg/kg | Intravenous |